Medicine, health care, and the wider social meaning and management of health are undergoing major changes. In part this refl ects developments in science and technology, which enable new forms of diagnosis, treatment and delivery of health care. It also refl ects changes in the locus of care and the social management of health. Locating technical developments in wider socio-economic and political processes, each book in the series discusses and critiques recent developments in health technologies in specifi c areas, drawing on a range of analyses provided by the social sciences. Some have a more theoretical, some a more applied focus but all draw on recent research by the authors. Th e series also looks toward the medium term in anticipating the likely confi gurations of health in advanced industrial society and does so comparatively, through exploring the globalization and internationalization of health.
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Emerging Technologies for Diagnosing Alzheimer's Disease Innovating with Care Th is series explores these processes within and beyond the conventional domain of 'the clinic', and asks whether they amount to a qualitative shift in the social ordering and value of medicine and health. Locating technical developments in wider socio-economic and political processes, each book discusses and critiques recent developments within health technologies in specifi c areas, drawing on a range of analyses provided by the social sciences.
Th e series has already published 15 books that have explored many of these issues, drawing on novel, critical, and deeply informed research undertaken by their authors. In doing so, the books have shown how the boundaries between the three core dimensions that underpin the whole series-health, technology, and society-are changing in fundamental ways. Th rough its focus on innovative diagnostic techniques being developed for Alzheimer's disease, this addition to the series provides new insights on these three core dimensions and their interaction, especially how innovation and care happen in many places beyond the clinic.
Th e editors of this collection have brought together a talented and diverse group of scholars, all concerned with the challenges posed by innovations in the diagnosis of Alzheimer's disease. Th e contributions highlight the instability and complexity of the challenges, as there remain controversies around the defi nition of Alzheimer's and certainly around its causes and diagnosis. Furthermore, there is no agreed-upon set of steps that patients or clinicians can take to prevent or treat the symptoms. Such uncertainty raises profound ethical questions about the desirability of diagnostic innovation-questions to which there are no simple answers. Th e editors and contributors show how values and practices underpin the meaning and use of diagnostic tools, but in doing so do not set out to judge the desirability of these tools for Alzheimer's. However, they do set out a number of conditions for conducting responsible innovation, with care and attention to the needs of patients and their loved ones, and how this should shape the work of clinicians and researchers. Th ey also demonstrate how care for present and future concerns becomes entangled in innovation practices.
Series Editors' Introduction vii
As series editors, we are confi dent that this collection will be of interest and value to diff erent audiences around the world, including policymakers and researchers concerned with innovation, health, and social policies and also those involved in fostering responsible innovation in genetics, biology, informatics, and the neurosciences. Marianne Boenink , Ph.D. is an assistant professor at the Department of Philosophy, University of Twente in the Netherlands. She has a background in health sciences and philosophy. Her research focuses on the conceptual, hermeneutical, and normative analysis of visions of the future of biomedicine and health care, and how these visions shape actual practices of biomedical innovation and vice versa. She is particularly interested in science and technologies pursuing 'personalized and predictive medicine'. She was project leader of the project 'Responsible early diagnostics for Alzheimer's disease', funded by the NWO programme 'Responsible Innovation', from which this volume emerged. Currently she leads a project on the early ethical and social assessment of new technologies to prognosticate patients in coma (also funded by NWO) and a Zon-MW project on the eff ects of involving patients and caregivers in dementia biomarkers research.
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Notes on Contributors xvi Notes on Contributors
Yvonne Cuijpers is preparing a doctoral thesis on the subject of responsible early diagnostics for Alzheimer's disease at the Innovation Studies Group at Utrecht University. She has a background in Philosophy of Science, Technology and Society. She is interested in the social construction and the social consequences of new technologies. She has previously worked on system innovation in animal husbandry and the implementation of alternatives for animal testing. He is currently writing a book about the molecularisation of cervical cancer screening in the USA, UK, and India, which explores in a comparative framework the development, evaluation, and adoption of DNA-based HPV tests as an alternative to the traditional pap smear. He has produced reports on intellectual property rights and regulatory frameworks in personalised medicine for the European Commission, Health Canada, and the Human Genetics Commission. existing diagnostic procedures . But most importantly, the novel tests are thought to reveal Alzheimer's at an early stage, possibly even years before the onset of symptoms. Early diagnosis of Alzheimer's disease (or AD) is indeed an important, worldwide goal of current research and development in the Alzheimer fi eld (Lock 2013 ). However, this goal raises controversy, in society, in healthcare, even among those active in Alzheimer research themselves. Proponents argue that an early diagnosis may help to plan one's future life-for example, by deciding whether to continue living in one's own house, by making care arrangements in a timely manner, and possibly, by signing a living will guiding decision making with regard to end of life. Moreover, medication is thought to be possibly more eff ective when started early. An early diagnosis, followed by early medication, might then help to keep the disease at bay. However, opponents counter that this hope is futile. Current medication slows down the disease, but does not cure it. Early diagnosis and early medication, thus, probably will just extend the time spent on worrying about one's mental capacities. What is the use of an early diagnosis, critics argue, if nothing can be done about the disease? Some even suspect that the whole search for early diagnostics is largely driven by an attempt of 'big pharma' to increase the market for their AD drugs. Whatever the motives driving R&D, the response to news items or blogs announcing diagnostic breakthroughs shows that people do indeed hold diff erent views about the desirability of early diagnosis for AD.
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From an ethical and societal perspective, the desirability of early diagnostics for AD is, then, not self-evident. As in other cases of emerging technologies, novel tests for AD raise the question whether we should do everything we can. Should early diagnostics for AD be introduced in society? Th is book delves into the issues raised by the promises of early diagnostics for AD by asking under which conditions emerging diagnostic technologies for AD could be considered a responsible innovation . Th is question entails more than a refl ection on the ethical and/or social acceptability 2 M. Boenink et al.
